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Eosinophils are circulating granulocytes involved in pathogenesis of asthma. A cascade
of processes directed by Th2 cytokine producing T-cells influence the recruitment of
eosinophils into the lungs. Furthermore, multiple elements including interleukin (IL)-5, IL-
13, chemoattractants such as eotaxin, Clara cells, and CC chemokine receptor (CCR)3 are
already directly involved in recruiting eosinophils to the lung during allergic inflammation.
Once recruited, eosinophils participate in the modulation of immune response, induction
of airway hyperresponsiveness and remodeling, characteristic features of asthma. Various
types of promising treatments for reducing asthmatic response are related to reduction in
eosinophil counts both in human and experimental models of pulmonary allergic inflam-
mation, showing that the recruitment of these cells really plays an important role in the
pathophysiology of allergic diseases such asthma.
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INTRODUCTION
Eosinophils are circulating granulocytes produced in the bone
marrow along with other white blood cells and travel at rela-
tively low levels in the bloodstream, making up 1–3% of white
blood cells. These are the major cell types that can be recruited to
sites of immunological or inflammatory responses (Huang et al.,
2009; Isobe et al., 2012; Uhm et al., 2012). The effector function
of eosinophils is related to their release of toxic granule proteins,
reactive oxygen species (ROS), cytokines, and lipid mediators (Liu
et al., 2006). Although eosinophils has been traditionally con-
sidered as cytotoxic effectors cells, new insights into molecular
pathways allowed a better understanding of the immunomod-
ulatory functions of these cells (Rosenberg et al., 2013). More
recently, eosinophils have also been demonstrated to participate
in host defense against respiratory viruses (Foster et al., 2008).
With the capacity of the eosinophils to store preformed cytokines,
chemokines, and growth factors available for immediate use, they
play multiple roles favoring the initiation and maintenance of
immune responses in inflammation, besides maintaining epithe-
lial barrier function, affecting tissue remodeling, and bridging
innate and adaptive immunity (Spencer et al., 2009; Shamri et al.,
2011). The local accumulation of eosinophils is involved in the
pathogenesis of allergic diseases such as asthma (Kato et al., 2006;
Isobe et al., 2012; Uhm et al., 2012).
Asthma is a chronic inflammatory disease in which several
inflammatory cells and mediators plays a role (Kikkawa et al.,
2012). Allergic asthma is associated with eosinophilic inflam-
mation in the airways (Lu et al., 2010). The proinflammatory
mediators derived by eosinophil are major contributors to inflam-
mation in asthma, including airway epithelial cell damage and loss,
airway dysfunction of cholinergic nerve receptors, airway hyper-
responsiveness, mucus hypersecretion, and airway remodeling,
characterized by fibrosis and collagen deposition (Kay, 2005; Watt
et al., 2005; Kanda et al., 2009; Walsh, 2010). Currently, the term
“eosinophilic asthma” has been used to characterize an asthma
phenotype with prevalence of eosinophils in the bronchial airways,
and this phenotype can be identified by peripheral eosinophil
count (Liang et al., 2012; Molfino, 2012; Spector and Tan, 2012).
Figure 1 summarizes the mode of action of eosinophils and its
importance to asthma.
Although eosinophils are cells studied for decades, many of the
mechanisms involved in eosinophilic inflammation and infiltra-
tion in tissues are still poorly understood (Akuthota et al., 2011),
mainly because eosinophils are likely to have both agonist and
antagonist activities on a variety of tissue resident immune cells,
such as mast cells (Lee et al., 2010).
Therefore, studies of eosinophils in human and animal models
of allergic airway inflammation help us to better understand the
importance of these cells in the pathogenesis of asthma.
MOLECULAR EVENTS IN EOSINOPHIL RECRUITMENT IN
ALLERGIC ASTHMA
Molecular mechanisms are involved in complex cell-signaling
pathways in allergic asthma. In this context, the activities of kinases
deserves much attention (Pouliot and Olivier, 2009). An important
kinase involved in the traffic and recruitment of eosinophils during
allergic inflammation is the phosphatidylinositol 3-kinase (PI3K),
belonging to a family of signaling molecules. These molecules
regulates the adhesion, distribution, and morphologic changes
of eosinophils, favoring the recruitment of these cells during
lung inflammation (Kang et al., 2012). Experimental studies have
been shown previously that PI3K inhibition attenuates eosinophil
recruitment into airways in models of asthma (Lim et al., 2009;
Park et al., 2010).
Rho-kinase is another important molecule involved in
eosinophil recruitment in asthma. It has also been shown that these
www.frontiersin.org April 2013 | Volume 4 | Article 46 | 1
Possa et al. Eosinophil recruitment in asthma
FIGURE 1 | Eosinophil recruitment in asthma. In the reaction of the
airway to antigen, Th2 cytokine producing T-cells as well as IL-5 and
eotaxin stimulates the release of eosinophils from bone marrow.
Elements like CC chemokine receptor (CCR3) also acting on eosinophil
recruitment to the lung. When eosinophils reach the airways through the
vasculature, they release granule proteins (ECP, EPO, MBP, and EDN)
with cytotoxic, immunological, and remodeling-promoting properties in
the lungs. ECP, eosinophil cationic protein; EPO, eosinophil peroxidase;
MBP, major basic protein; EDN, eosinophil-derived neurotoxin. Adapted
from Ghosh et al. (2013).
molecules participating in the infiltration of inflammatory cells
into the airways in allergic inflammation, probably suppressing
chemokine and cytokines, such as eotaxin, IL-5 and IL-13, related
to the pathophysiology of asthma, subject that will be discussed
further below (Taki et al., 2007; Possa et al., 2012).
Leukotrienes are another important set of molecules currently
related to eosinophilic infiltration in asthma. Especially cysteinyl
leukotrienes, mediators, and modulators in the pathophysiol-
ogy of asthma, are related to the survival and recruitment of
eosinophils to inflamed tissue (Busse and Kraft, 2005). Further-
more, leukotriene B(4) [LTB(4)] have been related to activation
and recruitment of various types of inflammatory cells, among
them eosinophils (Ohnishi et al., 2008). The beneficial effects in
allergic inflammation and eosinophil infiltration achieved with
the use of leukotrienes inhibitors will be discussed below. Anyway,
it is important to emphasize here that eosinophilic recruitment
into the inflamed airway in asthma is dependent of important
molecular and cellular mechanisms.
EOSINOPHILS AND PULMONARY INFLAMMATION
Despite the controversy surrounding the true effector function
of eosinophils in allergic airway inflammation, several studies
have been demonstrating the importance of eosinophils in dif-
ferent pathways in experimental models of asthma. Modulation
of immune response, induction of airway hyperresponsiveness
and remodeling appear to be the main function of the recruited
eosinophils in asthma (Trivedi and Lloyd, 2007).
IMMUNE RESPONSE
Asthma is an inflammatory disease in which multiple inflam-
matory mediators and modulators play function. In asthma,
eosinophils are found in increased numbers in the circulation and
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sputum (Busse and Sedgwick, 1992). Allergen challenge in animal
models of allergic inflammation is related to eosinophilia in bone
marrow, blood, and lung (Lu et al., 2010). They are cells with mul-
tiple functions that interact complexly with other immune cells
and their local environment (Akuthota et al., 2011).
With the allergic reaction of the airway to antigen, a cascade
of processes directed by Th2 cytokine producing T-cells starts,
which results in the attraction of eosinophils to the airway (Busse
and Sedgwick, 1992; Wardlaw, 1999). As a consequence of expo-
sure to the antigen, the release of eosinophils from bone marrow
is mainly influenced by interleukin (IL)-5 and specific chemoat-
tractants, such as eotaxin (Brightling, 2001). Recent investigation
revealed Clara cells, important part of the “immunomodulatory
barrier”of the airway epithelium, as the principal source of eotaxin
in the lung (Sonar et al., 2012). It is also believed that exposure
to the antigen induces trafficking of IL-5-producing T lympho-
cytes to the bone marrow, further promoting eosinophilopoiesis
through IL-5 signaling (Gauvreau et al., 2009). IL-13 is also
related to eosinophilia in asthma. This cytokine acts on IL-5
and eotaxin, which in turn selectively stimulate eosinophils. IL-5
is related to eosinophilia throughout the lung, whereas eotaxin
regulates the distribution of airways eosinophils (Pope et al.,
2001).
However, during episodes of allergic asthma, other elements
like CC chemokine receptor (CCR)3 are already directly involved
in recruiting inflammatory cells, particularly eosinophils, to the
lung (Das et al., 2006). The Clara cells contribute to the infiltra-
tion of eotaxin-responsive CCR3+ immune cells and augment the
allergic immune response in the lung (Sonar et al., 2012). Thus,
IL-5 and IL-13 signaling for Th2 cell function are not necessarily
mutually exclusive effectors mechanisms in eosinophil recruit-
ment, but participate together with other pathways to regulate
the allergic disease (Mattes and Foster, 2003).
Thus, even in the absence of IL-5, other factors including a cas-
cade of vascular cell adhesion molecule-1, intercellular cell adhe-
sion molecule-1, CC chemokines, and granulocyte-macrophage
colony-stimulating factor (GM-CSF) are capable of maintain suf-
ficient eosinophilic infiltration and their effector functions (Kato
et al., 2006).
After attraction, locally generated IL-4 and IL-13 promote
increased adhesion of the target organ vasculature to the
eosinophils, and factors such as IL-5 and GM-CSF promote the
local survival of eosinophils for long periods (Brightling, 2001).
Even factors expressed by airway epithelial cells, including nerve
growth factor and brain-derived neurotrophic factor (BDNF),
promote survival of tissue eosinophils during allergic airway
inflammation (Hahn et al., 2006).
Eosinophils regulate the immune response through direct
effects on T-cell activities (Jacobsen et al., 2012). Both Th1
and Th2 cytokine generation by CD4(+) T-cells are also influ-
enced by eosinophils (Liu et al., 2006; Esnault et al., 2012). In
brief, eosinophils regulate the allergen-dependent Th2 pulmonary
immune responses mediated by dendritic cells and T lymphocytes,
as well as suppress Th1 responses (Jacobsen et al., 2011). And
the eosinophils only release their granule proteins with cytotoxic,
immunological, and remodeling-promoting properties when they
reach the target organ, in this case the lungs, showing that these
cells have basically local effects on inflammation (Malm-Erjefält
et al., 2005).
When activated, eosinophils release leukotrienes (products
of oxidative metabolism) and other substances such as growth
factors and metalloproteinases involved in airway remodeling.
The leukotrienes liberated from mast cells and eosinophils are
also potent bronchoconstrictors and perpetuate the migration of
eosinophils to the airways (Vignola et al., 2000; Hendeles et al.,
2004; Lemanske and Busse, 2010).
Neurokinins such as Substance P (SP) and Neurokinin A (NKA)
are small neuropeptides that also plays a significant role in priming
eosinophils in allergic inflammation (Numao and Agrawal, 1992;
Tibério et al., 1997). It has been shown that neurokinins influence
eosinophil chemotaxis (Weinstock et al., 1988; Sagara et al., 1993).
Furthermore, Tibério et al. (2003) demonstrated that both SP and
NKA contribute to eosinophil lung recruitment in distal airways
and in alveolar wall, and these findings suggest that neurokinins
may contribute to the development of eosinophilic inflammation
in both allergic asthma and hypersensitivity pneumonitis. These
data show that modulation by neurogenic response is also very
important for the recruitment of eosinophils.
Even stress may amplify the eosinophilic infiltration in both
airways and lung parenchyma among animals with allergic inflam-
mation via immune response, demonstrating that these cells prob-
ably contribute to asthmatic response related to stress (Leick et al.,
2012; Marques et al., 2012). It is well known that some modulators
of the stress response have different effects on eosinophil recruit-
ment (Nittoh et al., 1998; Machida et al., 2005), but is important
to note that the complexity of these interactions still needs better
clarifying.
Thereafter, a series of events contribute to the arrival of
eosinophils in the airways, promoting obstruction, injury, and
bronchial hyperresponsiveness (Busse and Sedgwick, 1992; Ward-
law, 1999).
AIRWAY HYPERRESPONSIVENESS
The association between airway hyperresponsiveness and inflam-
mation is a characteristic feature of asthma [Global Initiative for
Asthma (GINA), 2011]. And airway hyperresponsiveness is a well-
established consequence of eosinophil infiltration (Kay, 2005; Watt
et al., 2005; Kanda et al., 2009; Kim and Lee, 2009; Walsh, 2010).
There is evidence that eosinophils are involved in the bronchial
hyperresponsiveness mediated by T-cell (Ohtomo et al., 2010).
Iwashita et al. (2006) showed in a murine model of airway hyperre-
sponsiveness that eosinophil chemotactic factor by T lymphocytes
(ECF-L) expression was observed soon after allergen exposure but
before the onset of airway inflammation, indicating that ECF-L is
a selectively expressed protein in the airway hyperresponsiveness
and may play a critical role in allergic inflammation.
The participation of IL-5 in stimulating eosinophils to induce
airway hyperresponsiveness is clear, once depletion of eosinophils
with antibody to IL-5 leads to blockage of hyperresponsiveness
(Kraneveld et al., 1997; Adamko et al., 1999; Leckie et al., 2000).
Furthermore, the direct effect of eosinophils in airway hyperre-
sponsiveness has already been previously demonstrated (Gundel
et al., 1991; Kanda et al., 2009). In ovalbumin (OVA)-sensitized
guinea pigs (GP), the treatment with antibody to eosinophil
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major basic protein prevented hyperresponsiveness. It seems like
eosinophil major basic protein leads to inhibition of neuronal M2
muscarinic receptor function on parasympathetic nerves in the
lungs, causing airway hyperresponsiveness (Evans et al., 1997).
Assuming that total eosinophil counts reflect asthmatic activity
and are useful for early detection of exacerbations, Schwartz et al.
(2012) demonstrated that there is a strong association between
eosinophil count in peripheral blood and airway hyperresponsive-
ness. Clinically, the quantity of eosinophils in the airways and spu-
tum is directly related to the degree of airway hyperresponsiveness
(Gibson et al., 2000; Obase et al., 2001).
REMODELING
Airway remodeling is the cellular and structural changes in the
airways, mainly resulting from repair processes in response to
persistent inflammation, and that contribute to irreversibility of
lung functions observed in asthma patients, including airway dys-
function and clinical symptoms observed in allergic asthma (Vig-
nola et al., 2000, 2003; Phipps et al., 2004; Fattouh and Jordana,
2008). Among structural changes can be noted subepithelial fibro-
sis, smooth muscle hypertrophy/hyperplasia, epithelial cell mucus
metaplasia, and increased angiogenesis (Aceves and Broide, 2008).
Eosinophils seem to contribute to airway remodeling in several
ways, including through release of eosinophil-derived mediators
such as transforming growth factor (TGF)-β, secretion of cationic
proteins, and cytokines, as well as through interactions with mast
cell and epithelial cells. Many of these factors can directly acti-
vate epithelium and mesenchymal cells, deeply related to the
development of airway remodeling (Kariyawasam and Robinson,
2007; Aceves and Broide, 2008; Venge, 2010). Eosinophil-derived
cytokines are in the modulation of Th2 responses that trigger
macrophage production of TGF-β1, which serves as a stimulus for
extracellular matrix production (Fanta et al., 1999; Holgate, 2001).
In addition, recent data demonstrated that eosinophils can also
contribute to airway remodeling during asthma by enhancing
airway smooth muscle (ASM) cell proliferation. Halwani et al.
(2013) verified that preventing eosinophil contact with ASM cells
using specific antibodies or blocking cysteinyl leukotrienes derived
from eosinophils was associated with inhibition of ASM prolifer-
ation. Moreover, ASM-synthesized cytokines seem to direct the
eosinophil differentiation and maturation from progenitor cells,
which can promote perpetuation of eosinophilic inflammation
and consequently the tissue remodeling in asthma (Fanat et al.,
2009).
EOSINOPHILS IN LUNG PARENCHYMA
The involvement of the lung parenchyma in the pathophysiology
of asthma is already well-established. Recently, it has been rec-
ognized that these distal lung alterations can corroborate global
pulmonary alterations, enhancing asthma symptoms (Dolhnikoff
et al., 1999; Rocco et al., 2001; Mauad et al., 2004; Xisto et al., 2005;
Lancas et al., 2006).
In this context, several authors have shown that eosinophilic
inflammation were present in the peripheral lung parenchyma
of asthmatic patients and in experimental animal models of
chronic pulmonary inflammation (Mauad et al., 2004; Xisto
et al., 2005; Lancas et al., 2006; Angeli et al., 2008; Araujo et al.,
2008; Nakashima et al., 2008; Starling et al., 2009). Thus, it is
important to note that not only the airways receive influence of
eosinophil recruitment in asthma, but that it also occurs in the
lung parenchyma.
RELATIONSHIP BETWEEN EXPERIMENTAL TREATMENTS
FOR CHRONIC PULMONARY ALLERGIC INFLAMMATION AND
EOSINOPHILS
Various types of promising treatments for reducing asthmatic
response are related to reduction in eosinophil counts both in
human and experimental models of pulmonary allergic inflam-
mation, showing that these cells really play an important role in
the pathophysiology of asthma.
Guinea pigs chronically exposed to OVA present an inflamma-
tory response predominantly eosinophilic, showing a significant
increase in eosinophil amount in airways, pulmonary parenchyma,
and bronchoalveolar lavage (BAL), constituting an interesting
experimental model to evaluate the participation of eosinophils
in allergic inflammation (Tibério et al., 1997; Leick-Maldonado
et al., 2004; Prado et al., 2005a,b; Lancas et al., 2006; Angeli et al.,
2008; Nakashima et al., 2008; Ruiz-Schütz et al., 2009; Leick et al.,
2012; Marques et al., 2012; Possa et al., 2012).
ANTI-LEUKOTRIENES
Cysteinyl leukotrienes are proinflammatory mediators with many
pulmonary actions, including human ASM contraction, chemo-
taxis, mucous secretion, smooth muscle proliferation, and increase
in vascular permeability (Drazen, 1998; Drazen et al., 1999; Hol-
gate and Sampson, 2000; O’Byrne, 2000). In vivo and in vitro influ-
ences of leukotrienes in chemotaxis of eosinophils have been previ-
ously shown. The treatment with montelukast, an anti-leukotriene
drug, was able to reduce eosinophils, with effects similar to dex-
amethasone treatment, in an experimental model of pulmonary
allergic inflammation in GP. The findings were correlated to
attenuation of airway response (Leick-Maldonado et al., 2004).
Blain and Sirois (2000) showed in sensitized mice that there was
a dose-dependent reduction in eosinophils in BAL by both dex-
amethasone and cysteinyl leukotriene-receptor antagonist. Muraki
et al. (2011) also used cysteinyl leukotrienes receptor antagonists
in OVA-sensitized GP and have found significant suppression of
eosinophil proliferation into BAL fluid and airways walls (Muraki
et al., 2011). Foster and Chan (1991) showed, in sensitized GP,
that the increase in eosinophil influx into airway submucosa was
attenuated by using a leukotriene-receptor antagonist. Henderson
et al. (2002) observed that montelukast treatment resulted in a
reduction of eosinophil infiltration in lung interstitium of mice
with chronic inflammation induced by OVA exposure.
Factors driving eosinophil influx induced by leukotrienes may
include IL-5 altered eosinophilopoiesis and release from the bone
marrow, reduced priming of eosinophils, altering the expression
of adhesion molecules, and reduced eosinophil apoptosis (Busse,
2001).
An in vitro study with montelukast showed that this antagonist
has inhibitory effects on epithelial cell cytokine secretion, includ-
ing secretion of IL-6 and IL-8, as well as on eosinophil survival,
suggesting the mechanisms by which leukotrienes exert their
functions on eosinophils in inflammation (Mullol et al., 2010).
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NITRIC OXIDE INHIBITION
It has already been demonstrated acute Nitric oxide (NO) inhibi-
tion, but not chronic treatment, by Nω-nitro-l-arginine methyl
ester (l-NAME) is associated with reduction of eosinophils in
the airway wall and lung parenchyma of OVA-exposed GP with
chronic pulmonary allergic inflammation, showing that NO plays
an important role in inflammatory cell recruitment (Prado et al.,
2005a,b; Angeli et al., 2008). The acute effects of NO inhibitors on
inflammatory cell recruitment have also been observed by other
authors (Feder et al., 1997; Schuiling et al., 1998).
Furthermore, it has been shown that l-NAME treatment
reduces the number of eosinophils positive for both neuronal
nitric oxide synthase (nNOS) and inducible nitric oxide syn-
thase (iNOS), while the treatment with 1400W, a highly selective
iNOS inhibitor, reduce only the iNOS-positive eosinophils, with-
out modifying the number of cells positive for nNOS (Prado
et al., 2006). Starling et al. (2009) also found that iNOS-specific
inhibition with 1400W reduces the eosinophil density in alveo-
lar septa of allergen-sensitized animals. These results confirm not
only the effectiveness of both treatments in exhaled NO reduction,
but also that NO production is very important to eosinophilic
recruitment.
Although there are several studies showing a role of NO in
inflammatory cell recruitment, no effects in eosinophil recruit-
ment are still a matter of controversy. Some authors showed
that acute treatment with non-selective inhibitors of NO reduced
allergen-induced eosinophilia (Feder et al., 1997; Iijima et al.,
2001). However, Eynott et al. (2002) demonstrated that specific
inhibition of iNOS reduced only neutrophils. Blease et al. (2000)
showed that single l-NAME dose increased peribronchial and BAL
fluid eosinophils in a murine model of fungal asthma. Ferreira et al.
(1998) demonstrated that chronic l-NAME treatment reduced
eosinophils in a model of acute inflammation. A recent study
showed that NO induces eosinophil apoptosis in a mechanism
mediated via ROS, c-jun N-terminal kinase (JNK), and later mito-
chondrial permeability transition (mPT) (Ilmarinen-Salo et al.,
2012).
These conflicting data between results may be related to the
fact that different protocols of antigen sensitization, antigen chal-
lenge, type of inhibitors used, and different species have been used.
Moreover, the concentration, flux and source of NO influenc-
ing eosinophilopoiesis, eosinophilic recruitment, and apoptosis,
with either anti- or pro-apoptotic properties may influence the
obtained results (Taylor et al., 2003).
ORAL TOLERANCE
Oral tolerance is associated with reduction of eosinophil recruit-
ment into distal airways and lung parenchyma, response that is
associated with attenuation of airways and lung tissue hyperre-
sponsiveness, as well with reduction in collagen and elastic fiber
deposition (Nakashima et al., 2008; Ruiz-Schütz et al., 2009).
Some authors also investigated the eosinophilic response
around the airways and speculated that the development of the
tolerance process was associated with the disappearance of the
Th2 lymphocyte population (Russo et al., 1998, 2001; Chung
et al., 2002; Keller et al., 2006). Vaickus et al. (2010) compared the
allergic pulmonary inflammation of allergen-sensitized mice sub-
mitted to oral tolerance treatment with different types of complex
mixture of insect components, and verified that oral tolerance was
related to reduction in eosinophil numbers in the BAL fluid and
eosinophil specific peroxidase activity in the lung homogenate,
demonstrating that oral tolerization is associated with reduction in
pulmonary eosinophilia. The decrease in eosinophilopoiesis with
oral tolerance demonstrates the idea of the importance of control-
ling the eosinophilic inflammatory response by immune response
modulation (Ruiz-Schütz et al., 2009).
RHO-KINASE INHIBITION
Rho-kinase is an effector protein of the Rho/Rho-kinase path-
way that is associated with Ca2+ sensitization to promote smooth
muscle contraction (Yoshii et al., 1999). Despite Rho-kinase is
mainly associated with airway hyperresponsiveness (Hashimoto
et al., 2002; Schaafsma et al., 2004, 2008), the infiltration of
inflammatory cells into the airways (Taki et al., 2007; Schaaf-
sma et al., 2008) is other important function of this effector
protein.
It has been recently demonstrated that the specific Rho-kinase
inhibition is associated with reduction in eosinophil recruitment
into airways in GP with chronic pulmonary allergic inflammation
(Possa et al., 2012).
Several studies have suggested that the RhoA/ROCK system
plays a role in eosinophil recruitment and Th1 and Th2 cytokine
secretion (Aihara et al., 2003, 2004; Henry et al., 2005). In this
regard, Henry et al. (2005) demonstrated that pretreatment with




IL-5, Il-13, and eotaxin Brightling (2001), Pope et al. (2001), Gauvreau et al. (2009)
CCR3 Mattes and Foster (2003), Das et al. (2006), Sonar et al. (2012)
Neurokinins Weinstock et al. (1988), Numao and Agrawal (1992), Sagara et al. (1993), Tibério et al. (1997)
Stress Nittoh et al. (1998), Machida et al. (2005), Leick et al. (2012), Marques et al. (2012)
Cysteinyl leukotrienes Foster and Chan (1991), Blain and Sirois (2000), Leick-Maldonado et al. (2004), Muraki et al. (2011)
Nitric oxide Feder et al. (1997), Ferreira et al. (1998), Iijima et al. (2001), Prado et al. (2006), Starling et al. (2009), Ilmarinen-Salo et al. (2012)
Oral tolerance Russo et al. (1998, 2001), Chung et al. (2002), Keller et al. (2006), Nakashima et al. (2008), Ruiz-Schütz et al. (2009), Vaickus
et al. (2010)
Rho-kinase Aihara et al. (2003, 2004), Henry et al. (2005), Taki et al. (2007), Zhu et al. (2011), Possa et al. (2012)
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Y-27632 reduced the number of eosinophils recovered from the
BAL fluid of OVA-sensitized mice. Taki et al. (2007) demon-
strated that another Rho-kinase inhibitor, fasudil, reduced the
numbers of eosinophils in BAL fluid, airways and blood ves-
sels. This Rho-kinase inhibitor also diminished the augmented
levels of IL-5, IL-13, and eotaxin in BAL fluid, demonstrating
that Rho-kinase pathway influences modulators of eosinophilic
recruitment.
Zhu et al. (2011) showed that at least two Rho-kinase isoforms,
ROCK1 and ROCK2, are associated with eosinophilic recruit-
ment in a model of OVA-challenged mice. Such results lead us
to think that both treatment with inhibitors of Rho-kinase as with
other drugs for suppressing eosinophilic inflammation and con-
sequently its deleterious effects, would be very beneficial in the
treatment of asthma.
Table 1 summarizes the several possible ways of eosinophil
recruitment in asthma, with some important references.
There are still controversies about if eliminating eosinophils
is a risk-free therapeutic strategy. Since eosinophils contribute to
defense against respiratory viruses, the elimination of these cells
may potentially increase the risk for viral infections, which may
predispose to the development of acute exacerbations of asthma,
an outcome that would have significant clinical implications
(Foster et al., 2008).
CONCLUSION
Increasingly consistent evidence suggests that eosinophils partici-
pate in a wide variety of functions in allergic lung inflammation.
In this context, it is important to consider this as a potential target
cell for the treatment of asthma. However, given the importance
of eosinophils in pathogenesis of asthma but also in lung defense
mechanisms, one must consider that the best way to treat asthma
should include not its complete elimination, but the partial control
of eosinophilic response.
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